Австралия - английски - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 80 mg - capsule, hard - excipient ingredients: poloxamer; gelatin; microcrystalline cellulose; hypromellose; sucrose; titanium dioxide; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 165 mg - capsule, hard - excipient ingredients: hypromellose; sodium lauryl sulfate; poloxamer; gelatin; microcrystalline cellulose; titanium dioxide; sucrose; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 125 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; gelatin; titanium dioxide; hypromellose; sucrose; iron oxide red; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: lactose monohydrate; dilute hydrochloric acid; polysorbate 80; disodium edetate; sodium hydroxide - fosaprepitant juno, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration),? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: disodium edetate; lactose; hydrochloric acid; sodium hydroxide; polysorbate 80 - fosaprepitant, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: ? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration) ? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: disodium edetate; polysorbate 80; hydrochloric acid; sodium hydroxide; lactose - fosaprepitant, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: ? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration) ? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - aprepitant - oral capsule - 125mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - aprepitant - oral capsule - 80mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - aprepitant - oral capsule - 125mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - aprepitant - oral capsule - 125mg